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Abstract
Background: Pharmaceutical opioid analgesic use continues to rise and is associated with potentially preventable
harm including hospitalisation for adverse drug reactions (ADRs). Spatial detection of opioid-related ADRs can
inform future intervention strategies. We aimed to investigate the geographical disparity in hospitalised ADRs
related to opioid analgesic use, and to evaluate the difference in patient characteristics between areas inside and
outside the geographic clusters.
Methods: We used the all-inclusive Admitted Patient Dataset for an Australian state (New South Wales, NSW) to
identify patients admitted for opioid-related ADRs over a 10-year period (July 2004 to June 2014). A space-time
analysis was conducted using Kulldroff’s scan statistics to identify statistically significant spatial clusters over time.
Relative risk (RR) was computed with p-value based on Monte Carlo Simulation. Chi-square test was used to
compare proportional difference in patient clustering.
Results: During the study period, we identified four statistically significant geographic clusters (RRs: 1.63–2.17)
during 2004–08; and seven clusters (RRs: 1.23–1.69) during the period 2009–14. While identified high-risk clusters
primarily covered areas with easier access to health services, those associated with socioeconomically
disadvantaged areas and individuals with mental health disorders experienced more unmet healthcare needs for
opioid analgesic safety than those from the rest of the State. Older people (≥65 years and over) accounted for
62.7% of the total study population and were more susceptible to opioid-related ADRs than younger people,. In the
first five-year period the clusters included a greater proportion of people with cancer in contrast to the second five-
year period in which there was a lesser proportion of people with cancer.
Conclusions: These results suggest that there is significant spatial-temporal variation in opioid-related ADRs and
future interventions should target vulnerable populations and high-risk geographical areas to improve safer use of
pharmaceutical opioid analgesics.
Keywords: Pharmaceutical opioid analgesics, Adverse drug reaction, Ageing, Health services
Background
Australia has a high and rapidly increasing use of pharma-
ceutical opioids [1–3]. Approximately 3 million Austra-
lians have at least one prescription of opioid analgesic
dispensed annually, most commonly codeine in combin-
ation with paracetamol, or oxycodone [1]. Australia’s total
annual opioid analgesic consumption is ranked 4th (per
capita) globally, with a 4-fold increase over the last decade
[2]. The cost to the Australian Federal Government of
subsidised opioid analgesics has increased more than 30-
fold over the last two decades ($AUD 271M in 2012) [3].
In addition to the Government subsidy, non-cancer pain
is another major driver of increased pharmaceutical opioid
analgesic use [4–6]. Adverse outcomes associated with
pharmaceutical opioid analgesic use, including premature
deaths, are on the rise [7–9].
Opioid prescribing practices demonstrate substan-
tial geographical variation [10–12]. There has been
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an increase in research applying spatial statistics
focusing on opioid analgesic use disorders and over-
doses [11, 13]. However much less is known about geo-
graphical patterns of adverse drug reactions (ADR),
another common concern in relation to therapeutic opioid
analgesic use [14–18]. Spatial scan statistics are widely ap-
plied in population health. These techniques identify po-
tential geographic clusters and compare the population
based relative risk for an event of interest [19]. Consider-
ing nearly half (45%) of hospitalised ADRs are preventable
[20], the application of spatial scan statistics has the clear
advantage in ADR surveillance to inform development of
intervention strategies.
Using an all-inclusive hospital inpatient dataset, this
study aimed 1) to investigate whether there were any
significant geographical clusters of opioid analgesic-re-
lated ADRs; and 2) to compare patient characteristics in-
side clusters with patients outside each identified cluster.
The ultimate goal is to inform potential prevention strat-
egies that may reduce ADR due to pharmaceutical opi-
oid analgesic use.
Methods
Data sources
We used the New South Wales (NSW) Admitted Patient
Data Collection (APDC) over the 10-year period from
July 2004 to June 2014, which is a complete census of
hospital separations in NSW, Australia. Maintained by
the NSW Health Department, the APDC comprises in-
formation and activities of admitted patients including
demographic and clinical information from all public
and private hospitals in NSW. Medical reasons for hos-
pital admission were coded at the time of discharge
using the 10th version of International Statistical Classi-
fication of Diseases and Related Health Problems Aus-
tralian Modification (ICD-10 AM) [21].
Based on the data use agreement with NSW Health
Department, we extracted demographic and clinical in-
formation for each de-identified separation record in-
cluding the patient’s age, sex, residential postcode,
private insurance status, and up to 53 medical diagnoses.
The Australian National University Science & Medical
Delegated Ethics Review Committee approved this study
(#2016/030), with the need for consent waived given the
use of de-identifiable data for secondary analysis.
Definitions
We used ICD-10 AM codes (Y45.0 Opioids and related
analgesics) from Chapter ‘External causes of morbidity
and mortality’ to select the hospitalised ADR incidents
caused by opioids ‘in proper therapeutic use’. [21] Data
on specific opioid analgesics were not available and
hereinafter ADRs refer to any use of opioid analgesics
related adverse drug reactions in general. Similarly, we
considered comorbid conditions in terms of hospitalised
major injury and disease groups widely reported as lead-
ing causes of death or clinical significant pain, i.e., cor-
onary heart diseases (ICD-10 AM codes I20–I25),
cerebrovascular diseases (I60–I69), cancers (C00–C97),
brain degenerative disorders in particular dementia and
Alzheimer disease (F01,F03, G30), chronic obstructive
respiratory diseases (J40–J44), and diabetes mellitus
(E10-E14), and osteoarthritis (M15-M19). There were
multiple updates to the ICD-10 AM during the study pe-
riods, which did not affect these codes.
Because the APDC consisted of de-identified episodes of
hospital care, we only considered cases admitted for acute
care based on their admission status being urgent to reduce
the impact of multiple counting of the same ADR event.
We excluded inpatients with unknown age and sex. We
categorised age into five groups, i.e., < 18, 18–44, 45–64,
65–84, or 85+ years; sex as male or female; private insur-
ance as yes or no; marital status as single or others; socio-
economic status as 1st (most disadvantaged), 2nd, 3rd, 4th,
or 5th (least disadvantaged) quintile using the postcode
based ‘Index of Relative Socioeconomic Disadvantage’, [22]
which summarises a range of economic and social condi-
tions specific to an area with a lower score indicating a rela-
tively greater disadvantage; rurality of residence as urban or
rural using the geographic Accessibility/Remoteness Index
of Australia plus (ARIA+) index quantifying remoteness in
terms of travelling distance to different size of population-
adjusted service centres [23]; convenience to pharmacies as
more convenient (i.e., most accessible to a pharmacy) or ra-
ther less based on the composite Pharmacy ARIA
(PhARIA) index measuring geographic remoteness (repre-
sented by ARIA+) as well as professional isolation (travel-
ling distance to the five closest pharmacies) [24]; severity of
comorbidities using revised Charlson Comorbidity Index
[25], as minor (score equal to 0), moderate (score equal to
1 or 2) or severe (score ≥ 3); and disposition status as either
died at hospital, or alive at discharge.
Statistical analysis
We carried out the space-time analysis using SaTScan
v9.6 [26]. Kulldroff’s scan statistics were used to identify
the presence of statistically significant spatial clustering
of the hospitalised opioid analgesic-related adverse reac-
tions across a total of 570 NSW Australian post-code
areas. This method progressively moves a cylindrical
scan window in space and time and calculates the ob-
served and expected number of cases for each post-code
area in this study [27]. For each post-code area, the ra-
dius of the scan window varied continuously in size from
zero to the 20% of the study population to account for
the small number of opioid-related adverse reactions at
postcode level. This window size was selected to gener-
ate high risk areas that make sense from a health system
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perspective (e.g. local government areas), as these could
then become the focus for locally delivered responses. In
addition we re-ran the model using window sizes from
10 to 25% for every 5% increase and found the results to
be very similar. We also examined the clusters year by
year and found the locations and the sizes of the clusters
varied greatly before and after 2009. Therefore we di-
vided the data into two five-years periods, 2004–05 to
2008–09 and 2009–10 to 2013–14. For count event data,
Poisson model was applied with population at postcode
level adjusted and relative risks (RRs) calculated for spe-
cific locations of clusters. We used the likelihood ratio
test to evaluate the statistical significance of an identified
cluster, with the p-value generated using Monte Carlo
Simulation [28]. The number of permutations was set to
999 to ensure adequate power for defining clusters, and
a p-value < 0.05 was set as statistically significant. The
scan window with the maximum likelihood value was
the most likely cluster. For secondary likely clusters, the
non-overlapping option was selected. Mantel-Haenszel
Chi-Square test was used to compare the proportional
differences in the characteristics of the study population
from identified clusters to those from the remaining re-
gions of NSW.
Results
A total of 26,776 opioid-related ADR incident cases
(reflecting the real incidence in the NSW residential
population) in 570 post-code areas from NSW were hos-
pitalised for acute care from 2004 to 05 to 2013–14,
demonstrating an overall increasing trend over time. Of
these 59.3% (n = 15,887) were females, 62.7% (n = 16,
802) were aged 65 years and over, and almost a quarter
(n = 5966) lived in the most socioeconomically disadvan-
taged areas (Table 1). Approximately 22.5% of the study
population were admitted for injurious conditions (e.g.
fractures of femur or rib) as the primary reason for ad-
mission, followed by conditions of the digestive systems
(e.g., constipation or intestinal obstruction) (17.2%) and
less well-defined bodily symptoms and signs (15.4%).
Spatial temporal pattern
During the five-year period of 2004–05 to 2008–09, four
statistically significant clusters of opioid-related ADRs
were identified with RRs in the range of 1.63 to 2.17
(Table 2). These clusters comprised 38.7% of total inci-
dents (n = 8403). While the second and third likely clus-
ters were closely connected, the other two clusters were
primarily isolated in regional NSW (Figs. 1 and 2).
During the five-year period of 2009–10 to 2013–14,
seven statistically significant clusters were identified with
RRs in the range of 1.23 to 1.69 (Table 2). These clusters
comprised 40.8% of total incidents (n = 18,373), and
demonstrated an increasing incidence in comparison to
Table 1 Characteristics of study population (n = 26,776)
Number (%)
Opioid-related ADRs by Year
2004–05 1215 (4.5)
2005–06 1464 (5.5)
2006–07 1756 (6.6)
2007–08 1774 (6.6)
2008–09 2194 (8.2)
V2009–10 2697 (10.1)
2010–11 3242 (12.1)
2011–12 3681 (13.7)
2012–13 4068 (15.2)
2013–14 4685 (17.5)
Age (years) of people involved in Opioid-related ADRs
< 18 614 (2.3)
18–44 4012 (15.0)
45–64 5348 (20.0)
65–84 11,388 (42.5)
85+ 5414 (20.2)
Gender
Male 10,889 (40.7)
Female 15,887 (59.3)
Marital status
Single 13,826 (51.6)
Others 12,950 (48.4)
Private Insurance
Yes 7754 (29.0)
No 19,022 (71.0)
Socioeconomic disadvantage
Most (1st quintile) 5966 (22.3)
Others (2nd to 5th quintile) 20,810 (77.7)
Rurality of residence
Urban 25,282 (94.4)
Rural 1494 (5.6)
Convenient access to pharmacy
More 24,087 (90.0)
Less 2689 (10.0)
Severity of comorbidities
Minor 15,835 (59.1)
Moderate 5845 (21.8)
Severe 5096 (19.0)
Disposition status
Alive 25,735 (96.1)
Dead 1041 (3.9)
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the previous five-year period. More clusters were identi-
fied in the metropolitan areas and the clusters identified
in the first five-year period along the coastlines were
spreading and covering more local government areas
(Figs. 1 and 2).
Cluster characteristics
In-hospital mortality was greater within the cluster pa-
tients compared to non-cluster patients in the first five-
year period, but this difference was not evident in the
second five-year period (Table 3). Similarly the identified
clusters had a higher proportion of patients from urban
areas or places with more convenient access to pharma-
cies during the first five-year period, and this propor-
tional difference was narrowing over time with a similar
higher proportion of incidents (> 90%) having conveni-
ent access to pharmacy between those clustered in the
identified regions and the rest of NSW.
During the first five-year period, the identified clusters
had a significantly higher proportion of patients with se-
vere comorbidities, or holding private insurance cover,
or living in less socioeconomic disadvantaged areas,
whereas during the second five-year period, there was a
turnaround in these proportions with identified clusters
comprising fewer patients with severe comorbidities, and
more patients from more socioeconomic disadvantaged
areas or without private insurance cover.
Cancers and diabetes accounted for the majority of the
selected clinical conditions in the study population.
Brain degenerative disorders and mental disorders were
over-represented in those from the identified clusters in
comparison to those from the rest of NSW over the 10-
year study period. While proportionally more patients
with cancer or coronary heart disease were observed in
those from the identified clusters during the first five-
year period, there appeared proportionally fewer people
with cancer or coronary heart disease during the second
five-year period..
Discussion
This study found substantial variability in space and time
with respect to the occurrence of opioid-related ADRs
for hospitalisation in NSW during the period of 2004 to
2014. We observed an increasing number of cases year
on year in the study population, which was consistent
with previous Australian and international findings that
point to an increasing healthcare burden arising from
opioid analgesic use [29–31]. This highlights the import-
ance of developing appropriate intervention strategies to
address this. The study demonstrated spatio-temporal
variation with earlier opioid-related ADRs being clus-
tered within post-code areas located in both metropol-
itan and regional local health districts, and more recent
clusters spreading and covering more metropolitan and
inner regional areas of NSW, coincident with high rates
of prescriptions being dispensed for opioid analgesics in
those areas [32]. Our study demonstrated the utility of
this approach. Future studies could build on this ap-
proach and include other data such as number of visits
to general practitioners, specialists, psychiatrists, phar-
macists, and allied health professionals to further elabor-
ate opioid-related ADR spatio-temporal variation to
assist the development of appropriate policy and health
service interventions.
We observed there were more patients from urban
areas with opioid-related ADRs in both five-year time
periods. More convenient access to pharmacies was
associated with an increase in opioid-related ADRs in
the earlier five-year period, but not the later one. We
found a potential shift over time in opioid-related
Table 2 Clusters of opioid-related adverse drug reactions for hospitalisation in NSW
Cluster No. post-code areas Observed cases Expected cases Log likelihood ratio Relative risk p-value
2004–05 to 2008–09
Most likely cluster 3 49 22.69 11.45 2.17 0.010
2nd 109 2599 1605.02 335.21 1.90 0.001
3rd 22 465 278.70 53.89 1.71 0.001
Least likely cluster 3 142 87.66 14.33 1.63 0.001
2009–10 to 2013–14
Most likely cluster 1 94 55.61 10.99 1.69 0.020
2nd 14 1015 635.27 99.99 1.63 0.001
3rd 2 201 127.29 18.26 1.59 0.001
4th 13 696 487.26 40.64 1.45 0.001
5th 121 4526 3452.59 191.41 1.41 0.001
6th 10 434 312.59 21.42 1.40 0.001
Least likely cluster 13 527 430.18 10.42 1.23 0.033
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Figure 1 1.1 Clusters of opioid-related ADRs for hospitalisation in NSW (Period: 2004-08). 1.2 Clusters of opioid-related ADRs for hospitalisation in
NSW (Period: 2009-14)
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ADRs towards more socioeconomically disadvantaged
population groups. Previous studies point to a poten-
tial link between greater health service utilisation and
opioid-related adverse events [33–35]. Our findings
raise questions regarding potential unmet healthcare
needs arising through a general lack of access to evi-
dence-based pain management services and this being
compounded in socioeconomically disadvantaged
population groups. Increasing both health professional
and targeted community focused educational activities
Figure 2 2.1 Most and least likely clusters of opioid-related ADRs for hospitalisation in NSW (Period: 2004-08). 2.2 Most and least likely clusters of
opioid-related ADRs for hospitalisation in NSW (Period: 2009-14)
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Table 3 Characteristics of study population from identified clusters in comparison to those from the remainder regions of NSW
2004–05 to 2008–09 2009–10 to 2013–14
Clusters
n (%)
Non-
clusters
n (%)
X2 p-
value
Clusters
n (%)
Non-clusters
n (%)
X2 p-
value
Total 3255 (100) 5148 (100) 7493 (100) 10,880 (100)
Age group (years)
< 18 77 (2.4) 141 (2.7) 0.005 161 (2.1) 235 (2.2) 0.396
18–44 509 (15.6) 820 (15.9) 1098
(14.7)
1585 (14.6)
45–64 625 (19.2) 1073 (20.8) 1403
(18.7)
2247 (20.7)
65–84 1404
(43.1)
2263 (44.0) 3252
(43.4)
4469 (41.1)
85+ 640 (19.7) 851 (16.5) 1579
(21.1)
2344 (21.5)
Gender
Male 1401
(43.0)
2032 (39.5) 0.001 3006
(40.1)
4450 (40.9) 0.288
Female 1854
(57.0)
3116 (60.5) 4487
(59.9)
6430 (59.1)
Marital status
Single 1605
(49.3)
2616 (50.8) 0.178 3946
(52.7)
5659 (52.0) 0.386
Others 1650
(50.7)
2532 (49.2) 3547
(47.3)
5221 (48.0)
Private insurance
Yes 1043
(32.0)
1269 (24.7) < 0.001 1941
(25.9)
3501 (32.2) < 0.001
No 2212
(68.0)
3879 (75.3) 5552
(74.1)
7379 (67.8)
Socioeconomic
disadvantage
1st (most) 589 (18.1) 1255 (24.4) < 0.001 2008
(26.8)
2114 (19.4) < 0.001
2nd 639 (19.6) 1114 (21.6) 1897
(25.3)
2050 (18.8)
3rd 609 (18.7) 997 (19.4) 1675
(22.4)
2092 (19.2)
4th 660 (20.3) 963 (18.7) 1385
(18.5)
1955 (18.0)
5th (least) 758 (23.3) 819 (15.9) 528 (7.0) 2669 (24.5)
Rurality of residence
Urban 3245
(99.7)
4649 (90.3) <.0001 7251
(96.8)
10,137
(93.2)
< 0.001
Rural 10 (0.3) 499 (9.7) 242 (3.2) 743 (6.8)
Convenient access
to pharmacy
More 3115
(95.7)
4399 (85.5) < 0.001 6752
(90.1)
9821 (90.3) 0.727
Less 140 (4.3) 749 (14.5) 741 (9.9) 1059 (9.7)
Disposition status
Death 196 (6.0) 196 (3.8) < 0.001 276 (3.7) 373 (3.4) 0.357
Alive 3059
(94.0)
4952 (96.2) 7217
(96.3)
10,507
(96.6)
Severity of comorbidities
Minor 1760 3023 (58.7) 0.005 4467 6585 (60.5) 0.995
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in relation to appropriate prescription and use of
pharmaceutical opioid analgesics should help to re-
duce these potentially preventable events.
The increase of opioid-related ADRs among older pa-
tients is of major concern, and is consistent with previous
findings that show opioid-related adverse outcomes in-
crease with age [36, 37]. Older adults are more likely to ex-
perience adverse outcomes from pharmaceutical opioid use
due to changes in their metabolic processes, highly preva-
lent co-morbidities, and the concurrent use of multiple
medications [38–42]. Lower rates of non-medical opioid
analgesic use among older adults compared with younger
people have also been observed [43]. With regard to the
significant increase in the use of prescription opioid analge-
sics in older people [44], second-line prescription opioids
have been commonly used to initiate pain management in
this patient population [45], as well as in those living with
mental health problems [46]. For both these patient popula-
tions there is an increased risk of ADRs [47–50]. Premature
deaths in relation to inappropriate use of pharmaceutical
opioid analgesics in the United States have been increasing
since 2006 in those who aged 60 years and above and have
exceeded those aged under 60 year since 2012 [43]. Emer-
ging evidence also indicates pharmaceutical opioid use in
older people is associated with elevated risk of cardiovascu-
lar disease mortality compared to non-users [16], and with
increased total mortality and hospitalisation among arthritis
patients [17]. Facing an ageing population and the vulner-
ability of older people to opioid-related ADRs, risk mitiga-
tion strategies should be implemented to ensure that the
potential benefits of any opioid prescription outweigh the
risks. Our study reinforces the importance of this both to
reduce harm to elderly patients arising from ADRs and re-
duce associated health care costs.
While prescribing opioids for the treatment of cancer
pain is appropriate, it is still a significant contributor to
the occurrence of adverse outcomes [51], with up to one
fifth of cancer patients experiencing intolerable adverse
events [52]. There is limited evidence of benefit for many
non-cancer pain conditions such as low back pain [53],
and prescribing opioids for non-cancer pain remains con-
troversial [54, 55]. For example, use in the treatment of
pain caused by diabetic neuropathy is deemed inappropri-
ate and should be avoided [56]. Noting these studies, we
observed an increasing pattern of opioid-related ADRs in
people with cancer or living with diabetes, which between
them accounted for the majority of cases with severe con-
ditions during the study period. We found the occurrence
of opioid-related ADRs was common in those with minor
comorbidities with 54% of patients in the earlier five-year
period and nearly 60% of patients in the second five-year
period experiencing ADRs. These observed patterns may
Table 3 Characteristics of study population from identified clusters in comparison to those from the remainder regions of NSW
(Continued)
2004–05 to 2008–09 2009–10 to 2013–14
Clusters
n (%)
Non-
clusters
n (%)
X2 p-
value
Clusters
n (%)
Non-clusters
n (%)
X2 p-
value
(54.1) (59.6)
Moderate 744 (22.9) 1073 (20.8) 1723
(23.0)
2305 (21.2)
Severe 751 (23.1) 1052 (20.4) 1303
(17.4)
1990 (18.3)
Clinical conditionsa
CHD 282 (8.7) 381 (7.4) 0.037 281 (3.8) 396 (3.6) 0.696
Cancer 578 (17.8) 795 (15.4) 0.005 983 (13.1) 1566 (14.4) 0.014
BDD 199 (6.1) 211 (4.1) < 0.001 373 (5.0) 379 (3.5) < 0.001
COPD 234 (7.2) 326 (6.3) 0.125 421 (5.6) 511 (4.7) 0.005
CVD 96 (2.9) 128 (2.5) 0.199 140 (1.9) 208 (1.9) 0.832
Diabetes 454 (13.9) 685 (13.3) 0.402 950 (12.7) 1402 (12.9) 0.679
Osteoarthritis 147 (4.5) 201 (3.9) 0.170 187 (2.5) 279 (2.6) 0.771
Number of
mental disorders
None 2436
(74.8)
4115 (79.9) < 0.001 5467
(73.0)
8346 (76.7) < 0.001
Single 674 (20.7) 869 (16.9) 1699
(22.7)
2232 (20.5)
Multiple (≥2) 145 (4.5) 164 (3.2) 327 (4.4) 302 (2.8)
aSelected clinical conditions including coronary heart diseases (CHD), cancer, brain degenerative disorders (BDD), chronic obstructive respiratory diseases
(COPD), cerebrovascular diseases (CVD), diabetes, and osteoarthritis, were compared between those with and without a condition, respectively
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relate to an overall increasing use of opioid analgesics in
healthcare settings [1–3], and/or lack of accredited multi-
disciplinary services for chronic pain in those local health
districts in regional NSW during the study period [57],
with greater use of potentially inappropriate opioid anal-
gesics in various clinical scenarios [49, 50].
We observed the high-risk clusters comprised more
people living with mental health problems than the rest of
NSW. This may indicate a lack of awareness of the risk of
pharmaceutical opioid analgesic use in mental health care
settings. While use of prescription sedative-hypnotics
predicts persistence in pharmaceutical opioid use [58],
their concurrent use would potentially create a lethal
combination.
With both more kinds of pharmaceutical opioid anal-
gesics being made available and more potent agents
within these, inappropriate use of these drugs and conse-
quent greater burden of opioid-related ADRs in the
healthcare systems is likely to occur. Given opioid anal-
gesics should be used with great care for cancer and
non-cancer pain [14, 53], and the evidence base inform-
ing therapeutic risk ratios is dynamic, regular updates of
guidelines is vital to underpin opioid prescribing, dis-
pensing and administration in all clinical settings. In
addition, healthcare provider organisations should in-
clude clinical audits in regard to opioid-related ADRs
and develop, implement, and evaluate targeted interven-
tion strategies to improve safer use of these agents.
Other strategies may include but not be limited to the
establishment of multidisciplinary and comprehensive
chronic pain services, and ensuring opioid-related ADR
risks are understood in all parts of the health system in-
cluding patient groups, general practice, community
pharmacy, residential aged care, and acute care settings.
Continuing professional development for health care
practitioners is key, as is raising community awareness
of the role these agents may safely play.
Global pharmacovigilance efforts are underway to ad-
dress the opioid epidemic. Our study describes geo-
graphical dimensions to the challenge in NSW and may
allow some priorities to be set taking into account the
observed geographical variation. Our study has some
limitations. First, the use of administrative inpatient data
with restricted contextual information limits our ability
to identify patient-level causal factors in relation to the
observed spatial-temporal variation. In this study we
were unable to measure opioid analgesic prescription,
dispensing, and administration patterns and relate these
to ADRs in specific clusters. Second, heterogeneity of
health service provision in relation to use of pharma-
ceutical opioid analgesics between geographic regions
may contribute in part to observed spatial-temporal pat-
terns in NSW. For example, hospital admission practices
may vary across different regions. Our findings indicate
a need for future investigation of local healthcare policy
and community programs that may influence appropri-
ate use of pharmaceutical opioids. Third, measurement
errors may occur while using the ICD-coded data with
some ADR cases being underreported in the administra-
tive data. Considering the APDC data has undergone
routine data quality checks, we deemed the impact due
to such errors minimal and unlikely to explain the ob-
served spatial-temporal patterns. This study focuses on
the adverse events associated with pharmaceutical opioid
use leading to acute admission to hospital. It is import-
ant to acknowledge that good clinical practice will con-
tinue to make appropriate use of these agents based on
evidence and careful consideration of the risk to benefit
ratio for a given patient.
Conclusion
These results suggest that there is significant spatial-
temporal variation in opioid-related ADRs in NSW.
Older people, people with mental health conditions,
people with less severe comorbidities, and people from
more socioeconomically disadvantaged areas were sus-
ceptible to opioid-related ADRs serious enough for acute
hospital care. Strategies should be developed, imple-
mented and evaluate to address opioid-related ADRs,
where possible taking account of the geographic and
temporal variations demonstrated.
Abbreviations
ADRs: Adverse drug reactions; ARIA+: Accessibility/Remoteness Index of
Australia plus; ICD-10 AM: 10th version of International Classification of
Diseases Australian Modification; NSW: New South Wales; PhARIA: Pharmacy
ARIA; RR: Relative risk
Acknowledgements
We thank the NSW Health Department for providing the APDC data.
Authors’ contributions
WD was a major contributor in the study design, data analysis, result
interpretation, and the first draft. SC, LL, DG, NG, and AJM contributed to
design, analysis, and interpretation of data and revising the manuscript
critically for important intellectual content. All authors read and approved
the final manuscript.
Funding
This study was supported by the NHMRC CRE Medicines and Ageing Small
Project Grants scheme. DG is supported by the NHMRC Dementia Leadership
Fellowship. The study funders had no further role in the study design, data
collection, analyses, interpretation of results, writing of the article, or the
decision to submit it for publication.
Availability of data and materials
No additional data are available.
Ethics approval and consent to participate
The Australian National University Science & Medical Delegated Ethics
Review Committee approved this study (#2016/030), with the need for
consent waived given the use of de-identifiable data for secondary analysis.
Consent for publication
Not applicable.
Du et al. BMC Pharmacology and Toxicology           (2019) 20:55 Page 9 of 11
Competing interests
The authors declare that they have no competing interests.
Author details
1Research School of Population Health, Australian National University,
Building 63, Eggleston Road, Acton, ACT 2601, Australia. 2South Western
Sydney Area Health Services, Sydney, Australia. 3Sydney Pharmacy School,
Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
4Charles Perkins Centre, University of Sydney, Sydney, Australia.
Received: 23 April 2019 Accepted: 26 August 2019
References
1. Department of Health. Post-market review of authority required PBS listings.
Opioid Roundtable: 2015, May 27.
2. Berterame S, Erthal J, Thomas J, et al. Use of and barriers to access to opioid
analgesics: a worldwide, regional, and national study. Lancet. 2016;
387(10028):1644–56.
3. Blanch B, Pearson S, Haber P. An overview of the patterns of prescription
opioid use, costs and related harms in Australia. Br J Clin Pharmacol. 2014;
78(5):1159–66.
4. Karanges E, Blanch B, Buckley N, et al. Twenty-five years of prescription
opioid use in Australia: a whole of population analysis using pharmaceutical
claims. Br J Clin Pharmacol. 2016;82(1):255–67.
5. Britt H, Miller G, Henderson J. A decade of Australian general practice
activity 2004-05 to 2013-14. General Practice Series 37. Sydney: Sydney
University Press; 2014.
6. Roger KD, Kemp A, McLachlan AJ, Blyth F. Adverse selection? A multi-
dimensional profile of people dispensed opioid analgesics for persistent
non-cancer pain. PLoS One. 2013;8(12):e80095.
7. Australian Institute of Health and Welfare. National opioid pharmacotherapy
statistics 2014, AIHW bulletin 128. Canberra: AIHW; 2015.
8. Roxburgh A, Bruno R, Larance B, et al. Prescription of opioid analgesics and
related harms in Australia. Med J Aust. 2011;195(5):280–4.
9. Pilgrim J, Yafistham S, Gaya S, et al. An update on oxycodone: lessons for
death investigators in Australia. Forensic Sci Med Pathol. 2015;11(1):3–12.
10. Webster BS, Cifuentes M, Verma S, et al. Geographic variation in opioid
prescribing for acute, work-related, low back pain and associated factors: a
multilevel analysis. Am J Ind Med. 2009;52(2):162–71.
11. Brownstein JS, Green TC, Cassidy TA, et al. Geographic information
systems and pharmacoepidemiology: using spatial cluster detection to
monitor local patterns of prescription opioid abuse. Pharmacoepidemiol
Drug Saf. 2010;19(6):627–37.
12. Islam M, McRae I, Mazumdar S, et al. Prescription opioid dispensing in New
South Wales, Australia: spatial and temporal variation. BMC Pharmacol
Toxicol. 2018;19:30.
13. Dwyer-Lindgren L, Bertozzi-Villa A, Stubbs R, et al. Trends and patterns of
geographic variation in mortality from substance use disorders and intentional
injuries among US counties, 1980-2014. JAMA. 2018;319(10):1013–23.
14. Chou R, Turner J, Devine E, et al. The effectiveness and risks of long-term
opioid therapy for chronic pain: a systematic review for a National Institutes of
Health pathways to prevention workshop. Ann Intern Med. 2015;162(4):276–86.
15. Baldini A, Von Korff M, Lin E. A review of potential adverse effects of long-
term opioid therapy: a practitioner’s guide. Prim Care Companion CNS
Disord. 2012;14(3):PCC.11m01326.
16. Khodneva Y, Muntner P, Kertesz S, et al. Prescription opioid use and risk of
coronary heart disease, stroke, and cardiovascular death among adults from
a prospective cohort. Pain Med. 2016;17(3):444–55.
17. Solomon D, Rassen J, Glynn R, et al. The comparative safety of analgesics in
older adults with arthritis. Arch Intern Med. 2010;170(22):1968–76.
18. Solomon D, Rassen J, Glynn R, et al. The comparative safety of opioids for
nonmalignant pain in older adults. Arch Intern Med. 2010;170(22):1979–86.
19. Kulldorff M, Heffernan R, Hartman J, et al. A space-time permutation scan
statistic for disease outbreak detection. PLoS Med. 2005;2(3):e59.
20. Hakkarainen K, Hedna K, Petzold M, et al. Percentage of patients with
preventable adverse drug reactions and preventability of adverse drug
reactions – a meta-analysis. PLoS One. 2012;7(3):e33236.
21. National Centre for Classification in Health. International statistical
classification of diseases and related health problems, 10th Revision,
Australian modification (ICD-10-AM). 5th ed. Sydney: National Centre for
Classification in Health; 2006.
22. Australian Bureau of Statistics (ABS). Information Paper 2039.0: an introduction
to socio-economic indexes for areas (SEIFA). Canberra: ABS; 2006.
23. Australian Institute of Health and Welfare (AIHW). Rural, regional and remote
health: a guide to remoteness classifications. Canberra: AIHW; 2004.
24. Lange J, Franzon J. Geographic access and spatial clustering of section 90
pharmacies −1990 to 2014: an exploratory analysis. Canberra: Department of
Health; 2016.
25. Quan H, Li B, Couris C, et al. Updating and validating the Charlson
comorbidity index and score for risk adjustment in hospital discharge
abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–82.
26. Kulldorff M, Rand K, Williams G. SaTScan: software for the spatial and space-
time scan statistics. Bethesda: National Cancer Institute; 2013.
27. Kulldorff M. A spatial scan statistic. Commun Stat Theory Methods.
1997;26(6):1481–96.
28. Kulldorff M. Prospective time periodic geographical disease surveillance
using a scan statistic. J R Stat Soc A Stat Soc. 2001;164(1):61–72.
29. Agency for Healthcare Research and Quality. Trends in opioid-related
hospitalizations. Available at: http://www.ahrq.gov/news/opioid-
hospitalization-map.html. Accessed 12 Oct 2018.
30. Zhang H, Du W, Gnjidic D, Chong S, Glasgow N. Trends in adverse drug
reaction related hospitalisations over 13 years in New South Wales,
Australia. Intern Med J. 2019;49(1):84–93.
31. Shei A, Hirst M, Kirson NY, et al. Estimating the health care burden of
prescription opioid abuse in five European countries. Clinicoecon Outcomes
Res. 2015;7:477–88.
32. Australian Commission on Safety and Quality in Health Care.
Australian Atlas of Healthcare Variation: Opioid medicines dispensing.
Available at: https://acsqhc.maps.arcgis.com/home/index.html.
Accessed 29 Mar 2019.
33. Rice JB, Kirson NY, Shei A, et al. Estimating the costs of opioid abuse and
dependence from an employer perspective: a retrospective analysis using
administrative claims data. Appl Health Econ Health Policy. 2014;12(4):435–46.
34. Gwira Baumblatt JA, Wiedeman C, Dunn JR, et al. High-risk use by patients
prescribed opioids for pain and its role in overdose deaths. JAMA Intern
Med. 2014;174(5):796–801.
35. Cochran BN, Flentje A, Heck NC, et al. Factors predicting development of
opioid use disorders among individuals who receive an initial opioid
prescription: mathematical modeling using a database of commercially-
insured individuals. Drug Alcohol Depend. 2014;138:202–8.
36. Cepeda M, Farrar J, Baumgarten M, et al. Side effects of opioids during
short-term administration: effect of age, gender, and race. Clin Pharmacol
Ther. 2003;74(2):102–12.
37. Chau D, Walker V, Pai L, et al. Opiates and elderly: use and side effects. Clin
Interv Aging. 2008;3(2):273–8.
38. World Health Organizations (WHO). World report on ageing and health.
Geneva: WHO; 2015.
39. Pretorius R, Gataric G, Swedlund S, et al. Reducing the risk of adverse drug
events in older adults. Am Fam Physician. 2013;87(5):331–6.
40. Elliott R, Booth J. Problems with medicine use in older Australians: a review
of recent literature. J Pharm Pract Res. 2014;44:258–71.
41. Mitchell S, Hilmer SN, McLachlan AJ. Clinical pharmacology of analgesics in
old age and frailty. Rev Clin Gerontol. 2009;19:103–18.
42. McLachlan AJ, Bath S, Naganathan V, et al. Clinical pharmacology of
analgesics in older people: impact of frailty and cognition. Br J Clin
Pharmacol. 2011;71(3):351–64.
43. West N, Severtson S, Green J, et al. Trends in abuse and misuse of prescription
opioids among older adults. Drug Alcohol Depend. 2015;149:117–21.
44. Roxburgh A, Ritter A, Slade T, et al. Trends in drug use and related harms in
Australia, 2001 to 2013. National Drug and Alcohol Research Centre: Sydney; 2013.
45. Gadzhanova S, Bell J, Roughead E. What analgesics do older people use
prior to initiating oxycodone for non-cancer pain? A retrospective database
study. Drugs Aging. 2013;30:921–6.
46. Campbell G, Nielsen S, Bruno R, et al. The pain and opioids IN treatment
(POINT) study: characteristics of a cohort using opioids to manage chronic
non-cancer pain. Pain. 2015;156(2):231–42.
47. Graziotti P, Goucke C. The use of oral opioids in patients with chronic non-
cancer pain: management strategies. Med J Aust. 1997;167(1):30–4.
48. Pergolizzi J, Böger RH, Budd K, et al. Opioids and the management of
chronic severe pain in the elderly: consensus statement of an international
Du et al. BMC Pharmacology and Toxicology           (2019) 20:55 Page 10 of 11
expert panel with focus on the six clinically most often used World Health
Organization step III opioids. Pain Pract. 2008;8(4):287–313.
49. Chou R, Fanciullo G, Fine P, et al. Clinical guidelines for the use of chronic
opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113–30.
50. Centre for Disease Control and Prevention. CDC Guideline for Prescribing
Opioids for Chronic Pain. Available at: https://www.cdc.gov/drugoverdose/
prescribing/guideline.html. Accessed 12 Oct 2018.
51. Wiffen PJ, Derry S, Moore RA. Impact of morphine, fentanyl, oxycodone or
codeine on patient consciousness, appetite and thirst when used to treat
cancer pain. Cochrane Database Syst Rev. 2014;5:CD011056.
52. Wiffen PJ, Wee B, Derry S, et al. Opioids for cancer pain - an overview of
Cochrane reviews. Cochrane Database Syst Rev. 2017;7:CD012592.
53. Abdel SC, Maher CG, Williams KA, et al. Efficacy, tolerability, and dose-
dependent effects of opioid analgesics for low Back pain: a systematic
review and meta-analysis. JAMA Intern Med. 2016;176(7):958–68.
54. Noble M, Treadwell J, Tregear S, et al. Long-term opioid management for
chronic noncancer pain. Cochrane Database Syst Rev. 2010;1:CD006605.
55. Manchikanti L, Ailinani H, Koyyalagunta D, et al. A systematic review of
randomized trials of long-term opioid management for chronic non-cancer
pain. Pain Physician. 2011;14:91–121.
56. Vuong C, Van Uum SHM, O’Dell LE, et al. The effects of opioids and opioid analogs
on animal and human endocrine systems. Endocr Rev. 2010;31(1):98–132.
57. NSW Ministry of Health. Report of the NSW pain management taskforce.
North Sydney: NSW Ministry of Health; 2012.
58. Lalic S, Gisev N, Bell JS, et al. Predictors of persistent prescription opioid
analgesic use among people without cancer in Australia. Br J Clin
Pharmacol. 2018;84(6):1267–78.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Du et al. BMC Pharmacology and Toxicology           (2019) 20:55 Page 11 of 11
